TABLE 3.

Comparison of patients infected with CDC strain USA100 with those infected with USA300a

Patient characteristicValue for group infected withb:P value
USA100USA300
Total patients10474
Median age (yr)5947<0.001
Male sex52 (50)46 (62)NS
Race
    Black75 (72)51 (69)NS
    White28 (27)21 (28)NS
    Other1 (1)2 (3)NS
Comorbidity
    None4 (4)14 (19)0.001
    HIV2 (2)4 (5)NS
    Diabetes mellitus43 (41)24 (32)NS
    Chronic kidney disease45 (43)14 (19)<0.001
    Hemodialysis31 (30)8 (11)0.003
    COPD11 (11)6 (8)NS
    Cardiovascular disease56 (54)13 (18)<0.001
    Neurologic disease30 (29)10 (14)0.016
    Liver disease16 (15)30 (41)<0.001
    Malignancy24 (23)8 (11)0.036
IVDU4 (4)37 (50)<0.001
Epidemiologic source
    Community associated7 (7)39 (53)<0.001
    Health care associated, community onset70 (67)26 (35)<0.001
    Health care associated, hospital onset27 (26)9 (12)0.024
Source
    CVC36 (35)9 (12)0.001
    Graft infection6 (6)1 (1)NS
    Infective endocarditis4 (4)14 (19)0.001
    Skin/wound19 (18)24 (32)0.030
    Respiratory tract9 (9)6 (8)NS
    Genitourinary tract8 (8)1 (1)0.054
    Intra-abdominal3 (3)0 (0)NS
    Multiple2 (2)3 (4)NS
    Unknown17 (16)16 (22)NS
Vancomycin E-test MIC
    1.04 (4)6 (8)NS
    1.571 (68)62 (84)0.019
    2.029 (28)6 (8)0.001
Daptomycin MIC
    0.256 (6)0 (0)0.037
    0.560 (58)38 (51)NS
    1.038 (37)36 (49)NS
Vancomycin heteroresistance7 (7)1 (1)0.086
  • a NS, not significant; COPD, chronic obstructive pulmonary disease.

  • b Values are no. (%) of patients unless otherwise noted.